- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
- 24 Jan 23 EFFECT Notice of effectiveness
- 23 Jan 23 424B3 Prospectus supplement
- 6 Jan 23 S-4/A Registration of securities issued in business combination transactions (amended)
- 19 Dec 22 S-4/A Registration of securities issued in business combination transactions (amended)
-
10 Nov 22 S-4 Registration of securities issued in business combination transactions
Exhibit 99.7
Consent to be Named as a Director Nominee
In connection with the filing by Imara Inc. (the “Company”) of the Registration Statement on Form S-4 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any and all amendments and supplements thereto as a person who has agreed to serve as a director of the Company following its merger with Enliven Therapeutics, Inc. (which shall be known as Enliven Therapeutics, Inc.) as described in the Registration Statement. I also consent to the filing of this consent as an exhibit to such Registration Statement and any amendments thereto.
Dated: October 31, 2022
By: | /s/ Richard Heyman | |
Name: | Richard Heyman |